RBC Capital Initiates Coverage On BridgeBio Pharma with Outperform Rating, Announces Price Target of $100

Benzinga Newsdesk www.benzinga.com Positive 82.6%

Neg 0% Neu 0% Pos 82.6%

RBC Capital analyst Luca Issi initiates coverage on BridgeBio Pharma (NASDAQ:BBIO) with a Outperform rating and announces Price Target of $100.